Daiichi Sankyo (OTCMKTS:DSNKY) Downgraded by Zacks Research to Strong Sell

Posted by Tyrone Williams on Aug 5th, 2026

Zacks Research cut shares of Daiichi Sankyo (OTCMKTS:DSNKY – Free Report) from a hold rating to a strong sell rating in a report published on Monday,Zacks.com reports.

Separately, Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Daiichi Sankyo has a consensus rating of “Reduce”.

View Our Latest Stock Analysis on DSNKY

Daiichi Sankyo Stock Performance

DSNKY stock opened at $16.00 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $27.50. The stock’s fifty day moving average is $16.49 and its two-hundred day moving average is $17.61. The stock has a market capitalization of $29.81 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 2.89 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts predict that Daiichi Sankyo will post 0.96 EPS for the current year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.